Skip to main content
CING
NASDAQ Life Sciences

Cingulate Finalizes Prospectus for Resale of 3.5M Shares Under Existing Lincoln Park Equity Line

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$6.4
Mkt Cap
$74.307M
52W Low
$3.2
52W High
$11.89
Market data snapshot near publication time

summarizeSummary

Cingulate Inc. filed a final prospectus for the resale of up to 3.5 million common shares to Lincoln Park Capital Fund, LLC, operationalizing a significant portion of its existing $25 million equity financing agreement.


check_boxKey Events

  • Finalizes Equity Line Share Resale

    Cingulate Inc. filed a prospectus for the resale of up to an additional 3.5 million common shares by Lincoln Park Capital Fund, LLC, under an existing equity purchase agreement.

  • Significant Potential Dilution

    The potential issuance of these 3.5 million shares would result in approximately 30.2% dilution to current outstanding shares.

  • Accesses Existing Capital Commitment

    This filing operationalizes the ability to draw on approximately $13.3 million remaining under the $25 million equity purchase agreement with Lincoln Park.

  • Critical for Going Concern

    Accessing this capital is vital for the company, which recently disclosed a going concern warning in its 10-K filing on March 18, 2026.


auto_awesomeAnalysis

This 424B3 filing finalizes the prospectus for the resale of an additional 3.5 million shares of common stock by Lincoln Park Capital Fund, LLC, under an existing $25 million equity purchase agreement established in July 2025. This follows the S-3 registration filed on March 19, 2026, which registered these shares. While Cingulate Inc. will not receive proceeds directly from Lincoln Park's resale, this prospectus enables the company to sell shares to Lincoln Park, with approximately $13.3 million remaining available under the agreement. This potential capital raise is substantial for the company, which recently disclosed a going concern warning in its 10-K. However, the issuance of these 3.5 million shares would result in significant dilution of approximately 30.2% for existing shareholders, based on current outstanding shares.

At the time of this filing, CING was trading at $6.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.3M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CING - Latest Insights

CING
Apr 28, 2026, 4:24 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Apr 14, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 27, 2026, 4:01 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Mar 26, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CING
Mar 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
CING
Mar 24, 2026, 5:13 PM EDT
Filing Type: 424B3
Importance Score:
9
CING
Mar 19, 2026, 6:00 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 18, 2026, 4:30 PM EDT
Filing Type: DEFA14A
Importance Score:
8
CING
Mar 18, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
CING
Mar 18, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9